The U.S. FDA granted Resolution Bioscience Inc. breakthrough device designation for its cell-free DNA (cfDNA) assay, currently under development as a qualitative, in vitro companion diagnostic (CDx) to detect homologous recombination deficiency (HRD) mutations and gene deletions.